

Pathway-Based Regulatory Toxicology and Alternatives to Animal Testing

Thomas Hartung

**Doerenkamp-Zbinden Professor and Chair for Evidence-based Toxicology, EHS
Director, Center for Alternatives to Animal Testing (CAAT)**

Joint appointment: Molecular Microbiology and Immunology

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, US

Professor of Pharmacology and Toxicology, University of Konstanz, Germany

Let's not beat a dead horse* talking once again about the shortcomings of toxicology and current alternative methods

***Completely inappropriate coming from CAAT**

Do not beat a dead horse.



No ACTUAL animals were harmed in the making of this cartoon.

Tox-20c

EBT



Tox-21c


**Omics, high-content, HTS
Bio-informatics
& -engineering**

**Pathways
of Tox (PoT)
*Human
Toxome***

**Integrated
Testing
Strategies
*ITS***

**Organo-typic
cultures
*Human-on-
Chip***

Human on Chip Approach




Could overcome many of these shortcomings, especially using stem cells

C. Zhang et al. (2009),
“Towards a human-on-chip:
Culturing multiple cell types
on a chip with
compartmentalized
microenvironments”

<http://en.wikipedia.org/wiki/Organ-on-a-chip>



The Johns Hopkins Center for Alternatives to Animal Testing



CAAT Information Day

Tuesday, May 22, 2012

10:00 am – 4:30 pm

Sheldon Hall (W1214)

Johns Hopkins Bloomberg

School of Public Health

615 North Wolfe Street

Baltimore, MD

New Approaches to Assessing Countermeasures to Bioterrorism Agents

Speakers include:

George Korch (JHBSPH and US DHHS)

William C. (Clint) Florence (DTRA)

Donald Drake (Sanofi-Pasteur)

Marti Jett (US Army)

Anthony Bahinski (Wyss Institute, Harvard)

Sonia Grego (RTI International)

Lisa Hensley (US FDA)

Thomas Hartung (CAAT)

Registration fee (including lunch): \$100 (free for the JHU community)

For registration and information, contact Marilyn Principe at mprincip@jhsph.edu



InfoDay 22 May 2012

Opportunities from countermeasures to bioterrorism

- Funding program (\$200 million) from NIH/FDA/DARPA/DTRA
- Need for predictivity, QA, validation
- Joint workshop 10 May 2013 FDA / NIH / DARPA / CAAT



EBT

Tox-20c



Tox-21c

**Omics, high-content, HTS
Bio-informatics
& -engineering**

**Pathways
of Tox (PoT)
*Human
Toxome***

**Integrated
Testing
Strategies
*ITS***


**Organo-typic
cultures
*Human-on-
Chip***

Scientific roadmap for the future of animal-free systemic toxicity testing



US Stakeholder Forum 30-31 May 2013 Hosted by FDA CFSSAN

Integrated Testing Strategies




- **Key contribution to REACH implementation process**
- **Use of different informations, not stand-alone replacement**



Food for Thought ... Integrated Testing Strategies for Safety Assessments


Thomas Hartung^{1,2}, Tom Luechtefeld¹, Alexandra Maertens¹, and Andre Kleensang¹

¹Johns Hopkins University, Bloomberg School of Public Health, CAAT, Baltimore, USA; ²University of Konstanz, CAAT-Europe, Germany




DISSEMINATION
PUBLICATIONS
PRESENTATIONS
WORKSHOPS

NAS vision report Tox-21c



EPA/100/K-09/001 | March 2009
www.epa.gov/osa

The U.S. Environmental Protection Agency's Strategic Plan for Evaluating the Toxicity of Chemicals



“With an advanced field of regulatory science, new tools, including functional genomics, proteomics, metabolomics, high-throughput screening, and systems biology, we can replace current toxicology assays with tests that incorporate the mechanistic underpinnings of disease and of underlying toxic side effects.” M.A. Hamburg, FDA 2011




“We propose a shift from primarily in vivo animal studies to in vitro assays, in vivo assays with lower organisms, and computational modeling for toxicity assessments”
F. Collins, NIH, 2008

Initiatives implementing Tox-21c


Organization	Approach	Purpose	Outcome
US EPA & Tox21 (ToxCast Program)	High-throughput testing	Chemical prioritization (initially)	“Biological signatures”
Hamner Institute	Case studies	“Just do it”	Proof-of-principle
NIH project (CAAT-US)	Pathway mapping	Pathway ID & annotation	Human Toxome

The concept of (finite number of) pathways of toxicity




- Annotation to:
- Hazard
 - Toxin (class)
 - Cell type
 - Species

Comprehensive list (Human Toxome)




Negatives

A) Homeostasis



B) Exogenous perturbation



Use for PoT identification:

- Homeostasis under stress, i.e. signatures of tox
- Critical cell infrastructures
- Network knowledge
- Reference models
- Reference toxicants



NIH Transformative Research Grant: *Mapping the Human Toxome by Systems Toxicology*

Consortium: Johns Hopkins (Hartung / Yager)
Brown (Boekelheide)
The Hamner (Andersen)
Georgetown (Fornace)
Agilent (Rosenberg)
EPA ToxCast (Kavlock, Dix)



GEORGETOWN UNIVERSITY



Mapping PoT from metabolomics and transcriptomics

In vitro systems

Toxicological endpoints



BROWN UNIVERSITY

Model Systems Characterization



JOHNS HOPKINS
BLOOMBERG
SCHOOL of PUBLIC HEALTH

In vitro treatments

omics data
generation

HC omics data
Metabolomics
& Transcriptomics



Software tools

Software for Statistics and
Pathways



Agilent Technologies

Visualization Tools

Pathways of Toxicity

Signature of Toxicity
Analysis



PoT Concept
Development

Human Toxome
Database

Pathway Validation



IV-IV Extrapolation

Toxcast, other data

PROPOSAL FOR A TEMPLATE, AND GUIDANCE ON DEVELOPING AND ASSESSING THE COMPLETENESS OF ADVERSE OUTCOME PATHWAYS




Figure 1. A schematic representation of the Adverse Outcome Pathway (AOP) illustrated with reference to a number of pathways.


PoT

Workshop on the Concept and Tools for Pathways of Toxicity
October 10 -12, 2012, Baltimore, MD

Human Toxome database

Content side:

- Mol.biol.
- Biochem.
- Omics SoT
- Tox Mechan.



PoT

User side:

- Regulation
- Probabilistic RA
- Systems Toxicology
- Virtual patient

Existing
databases

PoToMaC - The Pathways of Toxicity Mapping Center



European branch?


Transformative
Research Grant:
*Mapping the
Human Toxome
by Systems
Toxicology*



7 companies, 3 stakeholders



*1st International Forum towards
Evidence-Based Toxicology (EBT)
October 15-18, 2007, Como, Italy*



Evidence-based Toxicology
“Evidence-based medicine goes toxicology!”

**Hoffmann and Hartung “Toward an evidence-based toxicology”,
Human Exp. Tox., 2006**



Mar 2011: US EBTC
Oct 2011: Secretariat at CAAT
Jan 2012: First conference hosted by EPA

Kick-off meeting of the Evidence-Based Toxicology Collaboration (EBTC) Europe



ebtc
Evidence-based Toxicology Collaboration

In conjunction with Eurotox Congress 2012 (Stockholm, Sweden)


June 17, 2012

15:30h - 17:30h

Radisson Blu Royal Viking Hotel • Vasagatan 1, Stockholm, Sweden

Complimentary Registration: <http://www.ebtoc.com>

EBT Collaboration Steering Committees



- [About Us](#)
- [Contact Us](#)
- [Meetings & Symposia](#)
- [Steering Committee](#)

What is Evidence-based Toxicology?

The Evidence-Based Toxicology (EBT) Collaboration has recently taken up the challenge of translating evidence-based approaches from medicine to toxicology. The Collaboration has closely coordinated steering committees in the US and Europe with members drawn from government agencies, academia, and industry. [More . . .](#)



LATEST NEWS

-  **US EBTC Receives Informal Tutorial on Systematic Reviews**
The US EBTC Steering Committee held an informal tutorial on systematic reviews (SRs) on July 23, 2012 at Johns Hopkins S...
-  **Kick-off meeting of the Evidence-Based Toxicology Collaboration (EBTC) Europe**
In conjunction with Eurotox Congress 2012 (Stockholm, Sweden) June 17, 2012 | 15:30h - 17:30h Radisson Blu Royal Vi...

Just became available (AltWeb or ALTEX website)

Workshop Report

Evidence-based Toxicology for the 21st Century: Opportunities and Challenges*

Martin L. Stephens¹, Melvin Andersen², Richard A. Becker³, Kellyn Betts⁴, Kim Boekelheide⁵, Ed Carney⁶, Robert Chapin⁷, Dennis Devlin⁸, Suzanne Fitzpatrick⁹, John R. Fowle III¹⁰, Patricia Harlow¹¹, Thomas Hartung¹, Sebastian Hoffmann¹², Michael Holsapple¹³, Abigail Jacobs¹¹, Richard Judson¹⁴, Olga Naidenko¹⁵, Tim Pastoor¹⁶, Grace Patlewicz¹⁷, Andrew Rowan¹⁸, Roberta Scherer¹, Rashid Shaikh¹⁹, Ted Simon²⁰, Douglas Wolf¹⁴, and Joanne Zurlo¹

Perspectives on Validation of High-Throughput Assays Supporting 21st Century Toxicity Testing

Richard Judson¹, Robert Kavlock¹, Matthew Martin¹, David Reif¹, Keith Houck¹, Thomas Knudsen¹, Ann Richard¹, Raymond R. Tice², Maurice Whelan³, Menghang Xia⁴, Ruili Huang⁴, Christopher Austin⁴, George Daston⁵, Thomas Hartung⁶, John R. Fowle III⁷, William Wooge⁸, Weida Tong⁹, and David Dix¹

Valid(ated) models and reference substances

Pathway Identification

Food for Thought ... Mechanistic Validation

**New
ALTEX**

Thomas Hartung^{1,2}, Sebastian Hoffmann^{2,3}, and Martin Stephens¹

¹Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA;

²University of Konstanz, CAAT-Europe, Germany; ³seh consulting, Paderborn, Germany


**Proof of pathway coverage
Reproducibility**

***Mechanistically
validated***

How to use PoT information for RA?

Weight of evidence, mechanistic interpretation

**TTC:
Point of
departure
tissue
concentration
plus QIVIVE**



**Prioritization for
testing**

**Grouping based
on SoT**

**Identification of
no hazard**

Emergency assessments

Simulation, virtual exp.

**Frontloading of tox;
Green Toxicology**

How to use PoT information in the future?

Systems Toxicology

Integrated Testing Strategies based on PoT assays



Probabilistic RA

Mechanistic validation

Species extrapolation

Biomarker identification for use in clinics and epidemiology

Personalized and mixture toxicology

*The difficulty lies, not in the new ideas,
but in escaping from the old ones.*

John Maynard Keynes

(1883 - 1946)